Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Hematologic Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Myelodysplastic Syndromes 3Leukemia, Myeloid, Acute 3beta-Thalassemia 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Hodgkin Disease 2Graft vs Host Disease 2Anemia, Refractory, with Excess of Blasts 2Virus Diseases 1Thalassemia 1Primary Myelofibrosis 1Non-Malignant Neoplasm 1Neurofibromatosis 1 1Neoplasm, Residual 1Myeloproliferative Disorders 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, B-Cell 1Influenza, Human 1Fanconi Anemia 1Cytopenia 1Chromosome Aberrations 1Chromosome 7, monosomy 1Anemia, Sickle Cell 1

Interventions

thymoglobulin 1fludarabine phosphate 1fludarabine 1Whole-Body Irradiation 1Stem Cell Transplantation 1Sirolimus 1Mycophenolic Acid 1Hematopoietic Stem Cell Transplantation 1Cyclophosphamide 1Antilymphocyte Serum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Non-Malignant Neoplasm × thymoglobulin × Clear all
NCT04083183 2025-12-18

Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases

Fred Hutchinson Cancer Center

Phase 1/2 Recruiting
40 enrolled
Other neoplasm

Non-Malignant Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡